Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With <i>BRCA</i> Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen Radioligand Therapy
In real-world setting, substantially lower OS in mCRPC is observed for <i>BRCA</i>- and <i>PTEN/TP53/RB1</i>-mutated patients, whereas no difference in first-line PFS could be computed. In Lu-PSMA-treated patients, worst outcomes were observed for <i>BRCA</i> patients.
Authors
- Daniel Groener (ORCID: https://orcid.org/0000-0001-7927-6226)
- Felix K.‐H. Chun (ORCID: https://orcid.org/0000-0001-8486-9536)
- Markus Graefen (ORCID: https://orcid.org/0000-0003-3609-3512)
- Henning Reis (ORCID: https://orcid.org/0000-0003-1373-5295)
- Thomas Steuber (ORCID: https://orcid.org/0000-0001-6963-6611)
- Peter Johannes Wild (ORCID: https://orcid.org/0000-0002-1017-3744)
- Derya Tilki (ORCID: https://orcid.org/0000-0001-7033-1380)
- Clara Humke
- Florestan Koll (ORCID: https://orcid.org/0000-0001-7828-3950)
- Philipp Mandel (ORCID: https://orcid.org/0000-0002-0760-7281)
- Mike Wenzel (ORCID: https://orcid.org/0000-0002-4338-0889)
- Amir Sabet (ORCID: https://orcid.org/0000-0003-3027-5083)
- Benedikt Hoeh (ORCID: https://orcid.org/0000-0002-4238-6584)
Institutions
- Goethe University Frankfurt (DE)
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Martini-Klinik (DE)
- University Hospital Frankfurt (DE)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1200/po-24-00645
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.84